Literature DB >> 17201046

Medical risk in patients with bipolar disorder and schizophrenia.

John W Newcomer1.   

Abstract

Patients with schizophrenia and bipolar disorder are vulnerable to developing key modifiable risk factors for cardiovascular disease, such as obesity, smoking, hypertension, dyslipidemia, and type 2 diabetes mellitus. In addition, mood stabilizers, anticonvulsants, and antipsychotic medications, which are commonly used to treat schizophrenia and bipolar disorder, have been linked to risk for adverse metabolic changes in patients. This review reports the prevalence of medical risk factors in the general population as well as in those patients with schizophrenia or bipolar disorder and discusses treatment strategies and lifestyle changes that patients can make in order to reduce their risks for certain diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17201046

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  23 in total

Review 1.  Risk of myocardial infarction and stroke in bipolar disorder: a systematic review and exploratory meta-analysis.

Authors:  M L Prieto; A B Cuéllar-Barboza; W V Bobo; V L Roger; F Bellivier; M Leboyer; C P West; M A Frye
Journal:  Acta Psychiatr Scand       Date:  2014-05-22       Impact factor: 6.392

2.  Does colocated care improve access to cardiometabolic screening for patients with serious mental illness?

Authors:  Amy M Kilbourne; Zongshan Lai; Nicholas Bowersox; Paul Pirraglia; Mark S Bauer
Journal:  Gen Hosp Psychiatry       Date:  2011-08-26       Impact factor: 3.238

Review 3.  The diagnosis and treatment of bipolar disorder: recommendations from the current s3 guideline.

Authors:  Andrea Pfennig; Tom Bschor; Peter Falkai; Michael Bauer
Journal:  Dtsch Arztebl Int       Date:  2013-02-08       Impact factor: 5.594

Review 4.  Abuse liability assessment of tobacco products including potential reduced exposure products.

Authors:  Lawrence P Carter; Maxine L Stitzer; Jack E Henningfield; Rich J O'Connor; K Michael Cummings; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

5.  Association of plasma ω-3 and ω-6 lipids with burden of disease measures in bipolar subjects.

Authors:  Simon J Evans; Masoud Kamali; Alan R Prossin; Gloria J Harrington; Vicki L Ellingrod; Melvin G McInnis; Charles F Burant
Journal:  J Psychiatr Res       Date:  2012-08-11       Impact factor: 4.791

6.  Excess heart-disease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors.

Authors:  Amy M Kilbourne; Nancy E Morden; Karen Austin; Mark Ilgen; John F McCarthy; Gregory Dalack; Frederic C Blow
Journal:  Gen Hosp Psychiatry       Date:  2009-08-27       Impact factor: 3.238

7.  The neuropharmacology of psychosis.

Authors:  Carol A Tamminga; John M Davis
Journal:  Schizophr Bull       Date:  2007-06-11       Impact factor: 9.306

8.  Smoking Cessation in Individuals With Serious Mental Illness: A Randomized Controlled Trial of Two Psychosocial Interventions.

Authors:  Melanie E Bennett; Clayton H Brown; Lan Li; Seth Himelhoch; Alan Bellack; Lisa Dixon
Journal:  J Dual Diagn       Date:  2015

9.  [S3 guidelines on diagnostics and therapy of bipolar disorders: development process and essential recommendations].

Authors:  A Pfennig; T Bschor; T Baghai; P Bräunig; P Brieger; P Falkai; D Geissler; R Gielen; H Giesler; O Gruber; I Kopp; T D Meyer; K H Möhrmann; C Muche-Borowski; F Padberg; H Scherk; D Strech; M Bauer
Journal:  Nervenarzt       Date:  2012-05       Impact factor: 1.214

10.  Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis.

Authors:  Virginia L Stauffer; Ilya Lipkovich; Vicki Poole Hoffmann; Alexandra N Heinloth; H Scott McGregor; Bruce J Kinon
Journal:  BMC Psychiatry       Date:  2009-03-28       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.